Tag Archives: TRPX

Therapix Biosciences Gets A Buy Rating From Laidlaw Analyst

Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix’s lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company’s strategy is to repurpose, reposition and improve the FDA approved cannabinoid for various....More>>>